Overview
- The executive order, signed Saturday in the Oval Office, directs agencies to speed research and regulatory reviews and to set a Right to Try path so eligible patients can access investigational psychedelics.
- FDA Commissioner Marty Makary said three priority review vouchers for serotonin 2A psychedelics will be issued next week, with possible approval decisions as soon as this summer.
- The order instructs the DEA and Justice Department to begin rescheduling reviews only after successful Phase 3 trials, and ibogaine and other psychedelics remain in Schedule I today.
- The plan authorizes at least $50 million for states to build programs and delivery models, centering early access on veterans with PTSD, depression and addiction that have not responded to standard care.
- Experts warn ibogaine can trigger dangerous heart rhythm problems and say any rollout will require strict screening, cardiac monitoring, trained staff and clear payment models before broader use.